Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pig brain tissue. It is a registered medicine in parts of Europe, Asia, and Latin America but is not FDA-approved. Its evidence base is unusually contested — this page presents both sides.
Overview
Cerebrolysin's claimed benefit is better recovery of brain function after injury — mainly ischemic stroke — and the honest answer on whether it works is: the highest-quality evidence disagrees with itself. Randomized trials and meta-analyses report meaningful gains in motor recovery and early neurological status; the Cochrane Collaboration's review of overlapping evidence concludes no demonstrated benefit. Few compounds on this site have an evidence file where both the positive and negative cases are this substantial, so the sections below give each its own numbers.
The positive evidence
- The CARS trial (2016): 205 stroke patients randomized within 24–72 hours to Cerebrolysin 30 mL/day IV or placebo for 21 days, alongside rehabilitation. Upper-limb motor function (Action Research Arm Test) at day 90 favored Cerebrolysin with a large effect size of 0.71 (Stroke 2016).
- The CARS meta-analysis (2017): pooling CARS-1 and CARS-2 (442 patients), motor recovery still favored Cerebrolysin (effect size 0.62 at day 90) with a number-needed-to-treat of about 7 (Neurological Sciences 2017).
- A 2025 meta-analysis of 14 RCTs (2,884 patients) found significantly better early neurological recovery on the NIHSS stroke scale (mean difference 1.39 points), though the gain in functional independence did not reach significance (Cureus 2025).
The negative evidence
The 2023 Cochrane systematic review — generally the strictest evidence standard in medicine — analyzed seven randomized trials with 1,773 participants and reached the opposite conclusion: Cerebrolysin probably makes little or no difference to death after acute ischemic stroke, no included study demonstrated a benefit on death-or-dependence, and moderate-certainty evidence suggested more non-fatal serious adverse events in treated patients (Cochrane Database of Systematic Reviews 2023). Cochrane's authors do not recommend its use for acute ischemic stroke.
Why serious reviewers disagree
The disagreement is largely methodological, and understanding it is the real education here. The positive analyses emphasize recovery endpoints (motor scales, NIHSS change) in trials pairing the drug with structured rehabilitation; Cochrane restricts itself to hard outcomes (death, dependence, serious harm), weighs trial quality and sponsorship conservatively, and finds the recovery-scale gains unconvincing. Both camps read overlapping trials. What a reader can safely conclude: Cerebrolysin is not a proven stroke therapy by the strictest standard, the signal that keeps it in research is concentrated in rehabilitation-phase motor recovery, and certainty will require larger independent trials that may never be run.
Beyond stroke — and what it is not
Cerebrolysin has also been studied in traumatic brain injury and in Alzheimer's and vascular dementia, with the same pattern of mixed, heterogeneous results across smaller trials, and it is used clinically for these indications in the countries where it is registered — parts of Europe, Asia, and Latin America. What it is not is a nootropic: there are no controlled trials showing cognitive enhancement in healthy people, and its studied role is injury recovery under medical supervision — daily infusions in a clinic, not a biohacking protocol. The research overview covers the full evidence file.